Eli Lilly is building a $4.5 billion facility in Indiana that will combine research and production, aiming to enhance manufacturing efficiency and accelerate the development of clinical trial medicines, the drugmaker said Oct. 2.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
